Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 7, 2006, Pages 1184-1188

  Mollison, Lindsay ^a,b   Totten, Leanne ^b   Flexman, James ^c   Beaman, Miles ^d   Batey, Robert ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d Department of Microbiology Western Diagnostic Pathology ^*  (Australia)

^e JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Chinese herbal drugs; Hepatitis C; Randomized controlled trials

Indexed keywords

ALANINE AMINOTRANSFERASE; CH 100; CHINESE DRUG; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOATING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS C; HUMAN; LETHARGY; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33745225205     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04320.x     Document Type: Article

References (22)

1. ANCAHCRD Hepatitis C Sub-Committee. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C virus Epidemic in Australia 2002. Darlinghurst, NSW : National Centre in HIV Epidemiology and Clinical Research, 2002.
2. Freeman AJ Dore GJ Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001 34 : 809 16.
3. Poynard T Ratziu V Charlotte F Goodman Z McHutchison J Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 2001 34 : 730 9.
4. Arachne J. Natural therapies and hepatitis C. In: Crofts N, Dore G, Locarnini S, eds. Hepatitis C: an Australian Perspective. Melbourne : IP Communications, 2001 155 71.
5. Wang B-E. Management of chronic Hepatitis B: treatment of chronic liver diseases with traditional Chinese medicine. J. Gastroenterol. Hepatol. 2000 15 ( Suppl. E67 70.
6. Arase Y Ikeda K Murashima N et al. The long term efficacy of glycyrrhzin in chronic hepatitis C patients. Cancer 1997 79 : 1494 500.
7. Flora K Hahn M Rosen H Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 1998 93 : 139 43.
8. Liu JP McIntosh H Lin H. Chinese medicinal herbs for chronic hepatitis B. Cochrane Database of Syst. Rev. 2000 4. Art. No.: CD001940. 10.1002/14651858.CD00140.
9. Hirayama C Okamura M Tanikawa K Yano M Mizuta M Ogawa N. A multicenter randomized controlled trial of Shosaiko-to in chronic active hepatitis. Gastroenterol. Jpn. 1989 24 : 715 19.
10. Oka H Yamamoto S Kuroki T et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995 76 : 743 9.
11. Batey RG Bensoussan A Fan YY Bollipo S Hossain MA. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal preparation CH100 in the treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 1998 13 : 244 7.
12. Batey R Cao Q. Effects of CH-100, a Chinese herbal medicine, on acute concanavalin A-mediated hepatitis in control and alcohol-fed rats. Alcohol. Clin. Exp. Res. 2000 24 : 852 8.
13. Li YM Batey R Ryan P. TCM protects against CCl4 mediated liver damage in the mouse. Am. J. Chin. Med. 2003 31 : 119 27.
14. Ware JE Snow KK Kosinski M Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA : The Health Assessment Laboratory, 2000.
15. Davdison F Simmonds P Ferguson JC et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J. Gen. Virol. 1995 76 : 1197 204.
16. Young KK Resnick RM Myers TW. Detection of hepatitis C RNA by a combined reverse transcription-polymerase chain reaction. J. Clin. Microbiol. 1993 31 : 882 6.
17. Cnaan A Laird NM Slasor P. Using the linear and mixed model to analyse repeated measures and longitudinal data. Stat. Med. 1997 16 : 2349 480.
18. Liu JP Manheimer E Tsutani K Gluud C. Medicinal herbs for hepatitis C virus infection Cochrane Database of Syst. Rev. 2001 4. Art. No.: CD003183. DOI: 10.1002/14651858.CD003183.
19. Loff B McKelvie H. Australia shaken by complementary medicines recall. Lancet 2003 361 : 1710.
20. McHutchison JG Gordon SC Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998 339 : 1485 92.
21. Dieperink E Willengring M Samuel B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 2000 157 : 6.
22. Schaefer M Engelbrecht MA Gut O et al. Interferon alpha and psychiatric syndromes: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002 26 : 731 46.